Kanker-actueel Lymfeklier cancer: an overview of important studies and recent developments in the regular care

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

General: study of 37 case studies with multiple forms of cancer from a test group of 810 patients with lymfklier cancer and whether or not certain how regular approach worked and this study gives nice insight into the different forms of cancer where other bodies also were lymfklier by cancer affected, whether or not with any other form of primary cancer or as uitzaaiïngen. Article update 5 February 2012

Irradiation-Radio therapy for non-Hodgkin's lymphoma stage III and IV gives remarkable longer period to relapse and low-grade significantly more total remissions (60% CR average 42 months long) despite one or multiple chemotherapy that has already been done, thus randomized phase III study in multiple hospitals in Belgium and Netherlands. Article update 5 February 2012

Irradiation: Non-Hodgkin patients younger than 30 years-who have become for irradiated lymfklier cancer-non-Hodgkin's and have survived this illness have approx. 40% greater chance of getting breast cancer afterwards. Article update 5 February 2012

Chemo: a combination of cyclophosphamide, and rituximab treatment Fludarabine, gives significantly better results on time to disease progression and survival in non-Hodgkin's and CLL chronic lymphocytic leukemia. Article update 5 February 2012

Chemo: a first approach with a single dose of Rituximab, cyclophosphamide, vincristine and doxorubicin plus dexamethasone (hyper CVAD) followed by Rituximab plus high-dose methotrexate-be high durable remissions cytarabine seen at new patients with an aggressive form of lympfomen mantelcel. The disease, however, the side effects and to related mortality were high in this approach. Article update 5 February 2012

Radio 2-jaars immunotherapies with chemo improves overall survival Zevalin with 35 percent after Autologous stem cell transplantation in cancer-non-Hodgkin's lymfklier compared to just chemo. Article published February 4, 2012

Stem cell transplantation (allogeneic) at relapse of non-Hodgkin's disease free five-year survival gives 43% and 48% overall 5 year survival emerges from phase II study with 44 patients with relapse of aggressive form of non-Hodgkin 's. Article update 5 February 2012

Vaccination-non-Hodgkins on ASCO 2006 when presented as promising treatment after good results from phase I and II trials and between results from phase III studies. Article update 5 February 2012

Lymfeklier cancer: an overview of important studies and recent developments in the regular care

Lymfeklier cancer-regular developments

Under regular topical we mention results of surveys and studies on topical developments of aromatase inhibitors chemo's, radiotherapy, surgery, angiogenesis inhibitors, vaccines, monoclonal resources, and other mainstream cancer treatments. Some with additional comments, other as we found on the internet.

Scroll in left column for studies and publications, all of which have to do with lymfeklier cancer . More about cancer you can find under lymfeklier cancer lymfeklier cancer types- and under and then under complementarycancer lymfeklier in alphabetical list.

Experiences of cancer patients are found under experience stories and/or via video in the top left button on this page.